862174-39-8

Upstream product

• 925240-94-4 (1R,2S)-1-(9H-fluoren-9-ylmethoxycarbonylamino)-2-vinylcyclopropanecarboxylic acid tert-butyl ester 
• 925240-91-1 (1R,2S)-1-(9H-fluoren-9-ylmethoxycarbonylamino)-2-vinylcyclopropanecarboxylic acid 
• 862175-12-0 (1R,2S)-1-amino-2-vinylcyclopropanecarboxylic acid t-butyl ester 
• 1044560-99-7 4-hydroxycyclopent-2-ene-1,2-dicarboxylic acid dimethyl ester 
• 746657-36-3 (1R,2S)-ethyl 1-amino-2-vinylcyclopropanecarboxylate 
• 862174-36-5 cis-5-[((1R,2S)-1-tert-butoxycarbonyl-2-vinylcyclopropyl)carbamoyl]-3-hydroxycyclopent-1-enecarboxylic acid methyl ester 
• 20430-72-2 7-methoxy-2-phenylquinolin-4-ol 

Downstream Products

• 862247-48-1 trans-5-[((1R,2S)-1-tert-butoxycarbonyl-1-vinylcyclopropyl)carbamoyl]-3-(7-methoxy-2-phenylquinolin-4-yloxy)cyclopent-1-enecarboxylic acid 

Relevant academic research and scientific papers

Macrocyclic Inhibitors of Hepatitis C Virus

Compounds of the formula (I): and N-oxides, salts and stereoisomers thereof wherein A is OR1, NHS(═O)pR2, NHR3, NRaRb, C(═O)NHR3 or C(═O)NRaRb wherein; R1 is hydrogen, C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl; R2 is C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl or NRaRb; R3 is C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl, —OC1-C6alkyl, —OC0-C3alkylenecarbocyclyl, —OC0-C3alkyleneheterocyclyl; wherein any alkyl, carbocyclyl or heterocycylyl in R1, R2 or R3 are optionally substituted p is independently 1 or 2; n is 3, 4, 5 or 6; denotes an optional double bond; Rq is H or when L is CRz, Rq can also be C1-C6alkyl; Ry and Ry′ are independently C1-C6alkyl; L is N or CRz; Rz is H or forms a double bond with the asterisked carbon; W is —CH2—, —O—, —OC(═O)NH—, —OC(═O)—, —S—, —NH—, —NRa, —NHS(═O)2—, —NHC(=0)NH— or —NHC(═O)—, —NHC(═S)NH— or a bond; R8 is an optionally substituted ring system containing 1 or 2 saturated, partially saturated or unsaturated carbo or heterocyclic rings have utility in the inhibition of NS-3 serine proteases, such as flavivirus infections.

Synthesis of novel potent hepatitis C virus NS3 protease inhibitors: Discovery of 4-hydroxy-cyclopent-2-ene-1,2-dicarboxylic acid as a N-acyl-l-hydroxyproline bioisostere

Potent tetrapeptidic inhibitors of the HCV NS3 protease have been developed incorporating 4-hydroxy-cyclopent-2-ene-1,2-dicarboxylic acid as a new N-acyl-l-hydroxyproline mimic. The hydroxycyclopentene template was synthesized in eight steps from commercially available (syn)-tetrahydrophthalic anhydride. Three different amino acids were explored in the P1-position and in the P2-position the hydroxyl group of the cyclopentene template was substituted with 7-methoxy-2-phenyl-quinolin-4-ol. The P3/P4-positions were then optimized from a set of six amino acid derivatives. All inhibitors were evaluated in an in vitro assay using the full-length NS3 protease. Several potent inhibitors were identified, the most promising exhibiting a Ki value of 1.1 nM.